Lead. People with idiopathic REM sleep behavior disorder (iRBD) are known to face a sharply elevated risk of developing Parkinson disease and related neurodegenerative conditions. But whether iRBD itself causes that neurodegeneration or simply shares common roots has been a stubborn open question. A new genetic epidemiology study now offers the strongest causal evidence to date: iRBD is a genetically driven causal risk factor for at least four distinct neurodegenerative diseases, and the relationship runs in only one direction.
What they found. Researchers at Zhejiang University applied three complementary genetic analysis methods, linkage disequilibrium score regression (LDSC), two-sample Mendelian randomization (MR), and colocalization analysis, to large genome-wide association datasets. The results pointed to significant causal effects of iRBD on several diseases:
- Dementia with Lewy bodies showed the strongest genetic correlation (rg = 1.63, P = 0.0002) and a substantial causal odds ratio (OR = 1.45, 95% CI 1.03 to 2.06, P = 0.035).
- Parkinson disease had an OR of 1.10 (95% CI 1.03 to 1.16, P = 0.003).
- Multiple sclerosis showed an OR of 1.09 (95% CI 1.02 to 1.17, P = 0.016).
- Alzheimer disease had a more modest but still significant OR of 1.02 (95% CI 1.00 to 1.03, P = 0.011).
Crucially, the reverse Mendelian randomization analysis found no causal relationship running from any neurodegenerative disease back to iRBD. The effect is strictly unidirectional. The only condition tested that showed no significant link was amyotrophic lateral sclerosis (ALS), where all analyses returned null results (all P > 0.05).
Why it matters. iRBD is one of the strongest known prodromal markers for synucleinopathies such as Parkinson disease and dementia with Lewy bodies. Up to 80 percent of people diagnosed with iRBD will eventually convert to a neurodegenerative condition. This study moves the evidence from association to causation by using genetic instruments as natural randomizers, ruling out confounding and reverse causation. The findings suggest that the pathological processes driving iRBD are not merely bystanders but active early contributors to neurodegeneration. This has implications for risk stratification, clinical monitoring, and the design of future neuroprotective trials targeting the prodromal phase.
Limits. The study relied on summary-level GWAS data from populations of predominantly European ancestry, so generalizability to other ancestries is uncertain. Mendelian randomization captures lifelong genetic effects, which may differ from the effects of interventions applied later in life. The modest odds ratios, while statistically robust, indicate small effect sizes that may not translate to strong individual-level prediction.
Bottom line. iRBD is causally linked to Alzheimer disease, Parkinson disease, multiple sclerosis, and dementia with Lewy bodies through shared genetic mechanisms, with no evidence of reverse causality. The findings solidify iRBD as a genetically grounded prodromal state worthy of targeted surveillance and early intervention research.
Source. Hong Ye, Jia-Li Wang, Qiu-Han Xu, Yu-Liang Gao. “Refining the link between REM sleep behavior disorder and neurodegeneration: Genetic correlation, Mendelian randomization, and colocalization evidence.” Medicine (Baltimore). 2026 Jul 10;105(28):e48922. PMID: 42432887.